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Summary
AIMS OF THE STUDY: To analyse emergency depart-
ment (ED) presentations related to acute medical prob-
lems after recreational use of prescription/over-the-
counter (OTC) drugs in two major Swiss hospitals in order
to identify the prevalence of specific drugs, vulnerable
groups, time trends and local differences which could have
major public health implications.
METHODS: Retrospective analysis of cases presenting
with signs/symptoms consistent with acute toxicity due to
recreational use of prescription/OTC drugs from May 2012
to August 2017 at the ED of the University Hospital of Bern
and from October 2013 to July 2017 at the ED of the Uni-
versity Hospital Basel. We investigated time trends, sex
differences, patient characteristics and consumption pat-
terns within three age groups (≥16 to <36 years; ≥36 to
<56 years; ≥56 years).
RESULTS: During the study period, 344 cases were in-
cluded out of 1715 ED attendances due to acute drug tox-
icity and a total of 412,557 ED presentations. The use of
prescription drugs in conjunction with illegal drugs was re-
ported in nearly half the cases. The most frequently re-
ported prescription drugs were benzodiazepines (64%, n
= 220) and methadone (13%, n = 45). Forty-eight percent
(n = 166) of all presentations occurred within the youngest
age group. The analysis of time trends showed a signif-
icant increase in presentations in the youngest and the
oldest groups in Basel (both p <0.05), while the trend re-
mained stable over time in Bern for all age groups. While
the number of presentations remained constant over time
for men and women in Bern, a significant increase was
found for the female cohort in Basel (p <0.05). Patients in
all age groups presented with toxicities of predominantly
minor severity.
CONCLUSION: The prescription/OTC drugs most fre-
quently leading to ED presentations after recreational use
were sedative substances. A large proportion of the pa-
tients belonged to the youngest age group. A significant
increase in presentations was seen in the youngest and
oldest age groups and within women in Basel. This infor-
mation can be used to inform health care providers so that
they can adapt their prevention and treatment strategies in
their communities.
Keywords: prescription drug abuse, over-the-counter
drug abuse, psychoactive substances, acute toxicity,
emergency room
Introduction
Psychoactive drugs are substances that alter brain func-
tions, consciousness or cognition. They are the substances
most often misused for non-medical purposes [1]. Psy-
choactive substances include not only illicit drugs such as
cocaine, cannabis and heroin, but also prescription drugs
like benzodiazepines, opioids and over-the-counter (OTC)
medications (e.g. dextromethorphan) [1]. The abuse of
psychoactive substances is widespread. It is estimated that
approximately one in four adults in the European Union
have consumed illegal substances at least once in their life-
time [2]. Globally, over 11% of people who abuse illicit
substances and/or prescription drugs are estimated to suffer
from substance use disorders [3]. In Europe, cannabis and
cocaine are the most commonly abused illegal substances
[4], while the most widely recreationally used prescription
drugs include opioids and benzodiazepines [1].
While the United States has a diverse drug abuse sur-
veillance system, using direct estimates of self-reported
drug use and administrative data on drug arrests and drug
treatment admissions [5, 6], data collection regarding pre-
scription drug abuse in Europe and Switzerland is sparse.
The European Drug Emergencies Network (Euro-DEN)
Plus project has been collecting data on acute intoxications
with recreational substances (illicit and prescription/OTC
drugs) and emergency presentations across Europe since
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2013 [7–9]. Two of the 31 European centres currently in-
volved in the project are the University Hospital in Basel
(since October 2013) and the Inselspital in Bern (since Jan-
uary 2016). An analysis of data from Bern in the timeframe
between May 2012 and April 2016 showed that nearly one-
fifth (18%) of emergency department (ED) presentations
due to acute intoxications were associated with benzodi-
azepines or other sedatives [10]. Similar data from Basel
showed that benzodiazepines were among the most com-
monly abused prescription drugs [11, 12].
The aim of the present study was to investigate the preva-
lence of specific drugs, age- and sex-related consumption
patterns and time trends of ED presentations related to
acute medical problems after recreational use of prescrip-
tion/OTC drugs in two major Swiss tertiary care hospitals
in order to identify susceptible groups and local differ-
ences, which could have major public health implications
for primary care givers.
Materials and methods
In this retrospective analysis, we included all patients pre-
senting with acute medical problems related to the recre-
ational use of prescription or OTC drugs to the ED of the
University Hospital of Bern between 1 May 2012 and 31
August 2017 and the ED of the University Hospital of
Basel between 1 October 2013 and 31 July 2017. Both EDs
are primary care facilities (walk-in patients) and tertiary re-
ferral centres for hospitals in the greater Bern and Basel
areas. The study was approved by the local ethics commit-
tees.
From the electronic patient chart databases of both EDs,
cases were extracted using a comprehensive full-text
search algorithm. This search identified all cases related to
abuse, intoxication or related terms, with a large number of
substance names including abbreviations and misspellings.
Data abstraction was performed in a standardised manner
based on the methodology used in the Euro-DEN/Euro-
DEN Plus project [8, 10–12]. All cases were reviewed
manually and patients with acute toxicity related to recre-
ational use of prescription/OTC drugs were included in our
analysis. We identified the drug(s) associated with the pre-
sentation based on the patient’s self-reported use, informa-
tion from bystanders or witnesses and the diagnosis of the
physicians assessing the patient at the ED. Abuse of pre-
scription/OTC drugs was defined as use of a drug with
a medical indication for recreational rather than for med-
ical purposes. For example, recreational use of the OTC
cough medication dextromethorphan was included, but not
the recreational use of caffeine pills, as they do not have a
medical indication. Furthermore, we excluded drugs with
the sole indication of substitution treatment for severe ad-
diction. For example, heroin (available in Switzerland for
substitution in severe heroin addiction) was excluded, but
cases with recreational use of methadone (labelled for sub-
stitution treatment but also for pain management) were
included. Further exclusion criteria were: intoxication in
the context of a suicidal attempt, isolated ethanol intoxica-
tion, symptoms of drug withdrawal, and complications of
chronic drug use (e.g. infected injection sites). Cases with
positive analytical tests without clinical signs of acute tox-
icity were not included.
We recorded the patient demographics (age, sex, hour and
weekday of ED admission), the substances involved, the
clinical symptoms, and the clinical outcome. Clinical fea-
tures included the Glasgow Coma Scale (GCS) score, heart
rate, blood pressure, respiratory rate, body temperature,
laboratory tests and electrocardiography (ECG) findings.
In cases where the GCS score was not recorded, “alert”,
“drowsy” or “coma” was used, based on the notes of the
treating clinician. We assessed the severity of poisoning
with the Poisoning Severity Score for grading acute poi-
soning [13]. Minor toxicity refers to mild, transient and
spontaneously resolving symptoms, moderate toxicity
refers to pronounced or prolonged symptoms, severe toxic-
ity indicates severe or life-threatening symptoms and fatal
indicates that the intoxication resulted in death.
In Bern, analytical results are based on urine drug screen-
ing using an immunoassay (Triage® TOX Drug Screen,
Alere, Cologne, Germany) for amphetamines, barbiturates,
benzodiazepines, cocaine, methadone, methamphetamines
(including MDMA), opiates, phencyclidine (PCP), tri-
cyclic antidepressants and tetrahydrocannabinol (cannabis)
[14]. Ethanol levels were estimated from osmolar gap. An-
alytical findings in Basel are based on CEDIA immunoas-
says (Thermo Fisher Scientific, Passau, Germany) for bar-
biturates, amphetamines (including MDMA),
benzodiazepines, cocaine, cannabis, methadone and hero-
in, and DRI immunoassays (Thermo Fisher Scientific, Pas-
sau, Germany) for tricyclic antidepressants and opiates.
Ethanol blood levels and γ-hydroxybutyrate (GHB) levels
were determined by an enzymatic assay. An additional liq-
uid chromatography-tandem mass spectrometry (LC-MS/
MS) analysis with a method covering over 770 substances
[15] was also available in some cases.
Data from Bern and Basel were also analysed separately to
identify local differences. The data were arranged by con-
secutive month/year of presentation, type of prescribed/
OTC substance(s) abused, co-abuse of other psychoactive
substances, age, sex, and severity of intoxication. We in-
vestigated time trends, sex differences and consumption
patterns within three age groups (young: ≥16 to <36 years;
middle-aged: ≥36 to <56 years; elderly ≥56 years). To in-
vestigate time trends, we fitted a linear regression with a
Poisson distribution, with time as the independent variable
and number of ED presentations due to prescription/OTC
drugs as the dependent variable. To further investigate sex
differences, two separate regressions were performed for
men and women. To find which age group has the greatest
potential for abusive behaviour, we analysed the frequency
of ED presentations in the three age groups. We further ex-
amined the severity of intoxication with prescription/OTC
drugs over time to see whether an increase or decrease in
intoxication severity could be found. The individual pre-
sentations at the ED were considered independent of each
other. Statistical significance was defined on the basis of
a two-sided nominal p-value of 0.05. Statistical analyses
were conducted using the statistical software R using a
generalised linear model (glm) with a Poisson distribution
(family = ‘Poisson’) to analyse count data on the number
of cases presented per month to identify time trends [16].
Differences were tested using the chi-square test for cate-
gorical variables where levels were recorded exclusively,
i.e. sex, age groups, ethanol co-ingestion.
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Results
During the study period there were 1715 cases of acute
recreational drug toxicity (818 in Bern and 897 in Basel)
among a total of 412,557 ED presentations (218,166 in
Bern and 194,391 in Basel). After applying the inclusion
and exclusion criteria, 344 cases related to acute toxicity
of prescription/OTC drugs were extracted and included in
the present analysis, of which 190 cases were retrieved in
Bern and 154 Basel, corresponding to 23% and 17% of
acute recreational drug toxicity ED attendances in Bern
and Basel, respectively. The mean patient age was 36 years
(SD 11.4, range 16–73). In total, 73% (n = 250) of patients
were brought to the ED by ambulance. The patient char-
acteristics are shown in table 1. No statistically significant
differences in sex, age groups and ethanol co-ingestion
were found between the two sites (table 1).
In both hospitals, the most frequently reported recreation-
ally used prescription drugs were benzodiazepines (64%,
n = 220 in both centres collectively; 66%, n = 126 in
Bern; 61%, n = 94 in Basel) (fig. 1). In Bern, benzo-
diazepines were followed by methadone (10%, n = 18),
(dex)methylphenidate and antidepressants (both 9%, n =
17) (fig. 1). In Basel, benzodiazepines were followed by
opiates other than methadone (18%, see below),
methadone (18%) and (dex)methylphenidate (11%) (fig.
1).
In both centres, the most commonly reported benzodi-
azepines were diazepam, lorazepam and midazolam. While
in Bern the most commonly used benzodiazepine was mi-
dazolam (33%, n = 41), followed by diazepam (22%, n
= 28) and lorazepam (15%, n = 19), in Basel diazepam
(29%, n = 27) was most frequently used, followed by lo-
razepam (21%, n = 20) and midazolam (16%, n = 15). In
14 (11%) and 29 (31%) cases, a further specification of the
benzodiazepine used was not available in Bern and Basel,
respectively. Following methadone (13%, n = 45), mor-
phine (50%, n = 21) and tramadol (14%, n = 6) were the
Table 1: Patient characteristics Bern and Basel.
Bern + Basel
(n = 344)
Number of cases (%)
Bern
(n = 190)
Number of cases (%)
Basel
(n = 154)
Number of cases (%)
Sex Female 126 (37) 73 (38) 53 (34)
Male 218 (63) 117 (62) 101 (66)
Age group
(years)
≥16 to <36 166 (48) 95 (50) 71 (46)
≥36 to <56 147 (43) 82 (43) 65 (42)
≥56 30 (9) 13 (7) 17 (11)
Unknown 1 (<1) 0 (0) 1 (<1)
Time of presenta-
tion
Night arrival (20:00–8:00) 163 (47) 82 (43) 81 (53)
Weekend arrival (Friday 17:00 to Monday 8:00) 131 (38) 73 (38) 58 (38)
Ethanol co-inges-
tion (self-report-
ed)
Yes 174 (51) 98 (52) 76 (49)
No 54 (16) 24 (13) 30 (19)
Not known 116 (34) 68 (36) 48 (31)
Drug use report-
ed
1 substance 134 (39) 83 (44) 51 (33)
>1 substance 210 (61) 107 (56) 103 (67)
>1 prescription/OTC 85 (25) 34 (18) 51 (27)
Co-use with an illicit drug 168 (49) 90 (47) 78 (51)
Figure 1: Reported prescription/OTC substances.
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most commonly used opioids in both centres collective-
ly. In Bern, the most commonly used opioids (other than
methadone) were morphine (35%, n = 5), tramadol (21%,
n = 3) and codeine or codeine-containing agents (21%, n =
3) (e.g. the cough syrup Resyl Plus®). In Basel, the most
commonly used opioids (other than methadone) were mor-
phine (61%, n = 17), tramadol (14%, n = 4), codeine (7%,
n = 2) and oxycodone (4%, n = 1). A further specification
of the consumed opioids was not reported in 3 (21%) and
4 (14%) cases in Bern and Basel, respectively.
The youngest age group had the most ED presentations
in both hospitals (table 1). In Basel, the analysis of time
trends showed a significant increase in presentations in the
youngest age group (p = 0.013; estimated increase in cas-
es per month = 0.02, 95% CI 0.006–0.043) and the old-
est group (p = 0.02; estimated increase in cases per month
= 0.05, 95% CI 0.011–0.093), while in Bern the trend re-
mained stable over time for all age groups (fig. 2). While in
Bern the number of presentations remained constant over
time for men (increase in cases of 0.0003 per month, p =
0.96) and women (decrease in cases of 0.002 per month,
p = 0.71) in Bern, a significant increase was found for the
female cohort in Basel (p = 0.032; estimated increase in
cases per month = 0.04, 95% CI 0.019–0.065) (fig. 3). The
male cohort in Basel showed a non-significant increase in
cases per month of 0.01 (p = 0.15).
Patients in all age groups in both cohorts presented with
toxicities of predominantly minor severity (fig. 4). One
fatal case occurred, in the mid-aged group in Bern: a
39-year-old female patient died due to a generalised brain
oedema, most likely as a consequence of hypoxia after oral
intake of an estimated dose of 180 mg methadone. While
the number of cases with minor severity increased signif-
icantly over time in Basel (p <0.001), with an increase of
Figure 2: Time trends in the number of presentations by age group in (a) Bern, (b) Basel.
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0.032 cases per month, the number of minor severity cases
in Bern decreased (p = 0.042). We checked for correlations
between the time trends of all types of severity and found
no statistical significance (fig. S1 in appendix 1).
Among all cases from both centres, co-use of ethanol was
reported in 49% (n = 37) of severe cases, 48% (n = 49) of
moderate severity cases and 54% (n = 88) of minor sever-
ity cases. The use of more than one substance (either pre-
scription/OTC or illicit drug(s)) was reported in 72% (n =
55) of severe cases, 69% (n = 71) of moderate severity cas-
es and 51% (n = 84) of minor severity cases in both cen-
tres collectively. The co-use of illicit substances was re-
ported in 55% (n = 42) of all severe cases, 56% (n = 58) of
all moderate severity cases and 41% (n = 68) of all minor
severity cases collectively. A detailed summary of the co-
used substances reported at each centre by severity of in-
toxication is shown in table 2. Three cases reported having
taken an unknown substance in addition to a prescription/
OTC drug in Basel. In Bern, no such cases occurred.
The patient symptoms are shown in table 3. Medical treat-
ment including e.g. intravenous fluid administration was
provided in 277 cases (81%) collectively, with 157 (83%)
cases in Bern and 120 (78%) cases in Basel. Tracheal intu-
bation was performed in 11 (3%) cases overall (6 (3%) cas-
es in Bern and 5 (3%) in Basel). Benzodiazepines and/or
antipsychotics were administered in 57 (17%) cases over-
all (32 (17%) in Bern and 25 (16%) in Basel). The data re-
garding discharge from the ED are summarised in table 4.
Discussion
This study describes presentations related to acute toxicity
after recreational prescription/OTC drug use at the EDs of
Figure 3: Time trends in the number of presentations by sex in (a) Bern, (b) Basel.
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two urban hospitals in Switzerland during a time period of
five (Bern) and four (Basel) years. In both hospitals, ap-
proximately one-fifth of presentations due to acute recre-
ational drug use were related to prescription/OTC drugs.
The typical patient was male and belonged to the youngest
age group. Benzodiazepines were the most commonly re-
ported prescription drugs used. Use of more than one sub-
stance was common, with use of more than one prescrip-
tion/OTC drug or co-use of illicit drug(s) in more than half
the cases in Bern and in two-thirds of the patients in Basel.
Ethanol co-use occurred in approximately half the cases in
both hospitals. There was one fatality, and further severe
complications included two cases of myocardial infarction.
Our time trend analysis showed an increase in presenta-
tions related to recreational use of prescription/OTC drugs
in the youngest and oldest group, and in the female cohort
in Basel.
The prescription/OTC drugs most frequently leading to
ED presentations after acute recreational intoxication were
benzodiazepines. In both hospitals, midazolam, diazepam
and lorazepam were the most commonly recreationally
used benzodiazepines, possibly reflecting the local avail-
ability on the black market or, more likely, prescription
trends of local physicians. However, the type of benzodi-
azepine was not always reported. The pattern seen in our
analysis is similar to that of prescription drug abuse seen
in Europe, where sedatives and hypnotics are among the
most commonly abused prescription drugs [17]. To im-
prove sleep, to cope with stress and to get high are the main
reasons reported for the abuse of sedatives and hypnotics
[18].
After benzodiazepines, methadone and other opioids were
the most commonly used prescription/OTC drugs in both
our cohorts. The only patient with a fatal outcome in our
analysis had used methadone belonging to her partner, who
Figure 4: Severity of intoxication by age group in Bern and Basel.
Table 2: Reported co-use patterns in Bern and Basel by severity of intoxication.
Ethanol co-use >1 substance (more than one pre-
scription/OTC or additional illicit
drug)
Co-use of illicit substance(s)
Both centres combined
n (%)
Minor (n = 164) 88 (54) 84 (51) 68 (41)
Moderate (n = 103) 49 (48) 71 (69) 58 (56)
Severe (n = 76) 37 (49) 55 (72) 42 (55)
Fatal (n = 1) na na na
Total (n = 344) 174 (51) 210 (61) 168 (49)
Bern
n (%)
Minor (n = 83) 44 (53) 39 (47) 31 (37)
Moderate (n = 64) 29 (45) 39 (61) 34 (53)
Severe (n = 42) 25 (60) 29 (69) 25 (60)
Fatal (n = 1) na 0 (0) 0 (0)
Total (n = 190) 98 (52) 107 (56) 90 (47)
Basel
n (%)
Minor (n = 81) 44 (54) 45 (56) 37 (46)
Moderate (n = 39) 20 (51) 32 (82) 24 (62)
Severe (n = 34) 12 (35) 26 (76) 17 (50)
Fatal (n = 0) na na na
Total (n = 154) 76 (49) 103 (67) 78 (51)
na = not applicable or information not available
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was under maintenance therapy. This highlights the impor-
tance of avoiding high permissible dosage dispensations.
Almost two-thirds (63%) of patients under substitution re-
ceive methadone in Europe [1]. In the last twenty years, the
use of prescription opioids has increased [19]. The lead-
ing motive for non-medical use in about 40% of cases was
pain relief. However, about every other user of non-med-
ical prescription opioids reported non-pain relief motives
only, e.g. to get drugged or to relax [20].
After benzodiazepines and opioids, the third most com-
monly abused prescription drug in our cohorts was
methylphenidate. An analysis in the US showed an in-
crease in the abuse of prescription stimulants in recent
years, especially among high school and college students
[21]. Reasons for using stimulants reported by US univer-
sity students were to increase their alertness and energy
[22]. Another study among Swiss secondary school stu-
dents showed that methylphenidate was the drug most fre-
quently used to enhance cognition [23].
Most ED presentations occurred in the youngest age group
in both hospitals. Teenagers and young adults especially
seem to believe that prescribed medications are safer than
illicit drugs, even when used illicitly [24, 25]. The moti-
vations associated with the abuse of prescription drugs by
teenagers are, among others, self-medication of e.g. anxi-
ety or insomnia, to enhance performance and to get high
or experiment, often in combination with alcohol [20, 24,
25]. Our analysis of time trends showed a significant in-
Table 3: Clinical presentations in Bern and Basel.
Bern + Basel
n = 344
Bern
n = 190
Basel
n = 154
Cardiovascular
n (%)
Chest pain 10 (3) 4 (2) 6 (4)
Palpitations 9 (3) 5 (3) 4 (3)
Dyspnoea 12 (3) 6 (3) 6 (4)
Hypertension (systolic blood pressure ≥180 mm
Hg)
9 (3) 8 (4) 1 (1)
Hypotension (systolic blood pressure ≤90 mm Hg) 16 (5) 13 (7) 3 (2)
Tachycardia (> 100 beats per minute) 70 (20) 40 (21) 30 (19)
Myocardial infarction 2 (1) 1 (1) 1 (1)
Arrhythmias 5 (1) 2 (1) 3 (2)
Psychiatric
n (%)
Anxiety, nervousness and/or fear 69 (20) 47 (25) 22 (14)
Psychosis 16 (5) 13 (7) 3 (2)
Hallucinations 18 (5) 13 (7) 5 (3)
Agitation and/or aggression 80 (23) 55 (29) 25 (16)
Panic attack 2 (1) 2 (1) 0 (0)
Insomnia 10 (3) 5 (3) 5 (3)
Suicidal ideation 3 (1) 3 (2) 0 (0)
Neurological
n (%)
Loss of consciousness (GCS <8) on presentation
or pre-hospital
12 (3) 3 (2) 9 (6)
Impaired consciousness (GCS <15) on presenta-
tion or pre-hospital
115 (33) 90 (47) 25 (16)
Vertigo and/or dizziness 15 (4) 10 (6) 5 (3)
Headache 10 (3) 7 (4) 3 (2)
Paraesthesia 5 (1) 2 (1) 3 (2)
Seizure 10 (3) 4 (2) 6 (4)
Tremor 9 (3) 6 (3) 3 (2)
Amnesia 13 (4) 9 (5) 4 (3)
Other neurological symptoms
n (%)
Miosis 55 16) 34 (18) 21 (14)
Mydriasis 25 (7) 15 (8) 10 (6)
Respiratory depression 56 (16) 35 (18) 21 (14)
Miscellaneous
n (%)
Hyperventilation 6 (2) 4 (2) 2 (1)
Nausea and/or vomiting 28 (8) 14 (7) 14 (9)
Sweating 10 (3) 9 (5) 1 (1)
Malaise 5 (1) 4 (2) 1 (1)
Abdominal pain 7 (2) 4 (2) 3 (2)
Hyperthermia (≥39.0°C) 2 (1) 1 (1) 1 (1)
Muscle cramps 7 (2) 5 (3) 2 (1)
Injuries (e.g., fracture, wound) 10 (3) 2 (1) 8 (5)
GCS = Glasgow Coma Scale
Table 4: Discharge data in Bern and Basel, n (%).
Bern + Basel
n = 344
Bern
n = 190
Basel
n = 154
Medically discharged home 182 (53) 100 (53) 82 (53)
Self-discharged 41 (12) 14 (7) 27 (18)
Admission to critical care unit 37 (11) 18 (9) 19 (12)
Admission to ward other than critical care unit 28 (8) 14 (6) 14 (9)
Admission to psychiatric clinic 56 (16) 44 (23) 12 (8)
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crease in presentations not only in the youngest, but also
in the oldest group in Basel. According to reviews of psy-
choactive drug abuse in elderly patients, the leading factors
for drug abuse are social isolation, history of substance-
use or mental health disorders and exposure to prescrip-
tion drugs with abuse potential [26]. Different approaches
compared to those for younger patients might be necessary
when treating abuse disorders in this patient population
[26]. The different spectrum of motivations in different age
groups requires intervention strategies that address the di-
versity of motivations.
In our study, a significant increase in presentations over
time was found for the female cohort in Basel. In previous
studies with chronic pain patients, women were found to
keep unused medications as well as using additional drugs
(e.g. sedatives) to enhance the effect of analgesics more
frequently than men [27]. Our results might also suggest
differences regarding the drug prescribing practices of
physicians towards men and women.
Although cases of minor severity increased over time in
Basel and decreased in Bern, the contrast with cases of
moderate and severe severity was not significant, thus in-
dicating that the increase in minor severity in Basel is not
related to a decrease of moderate and severe severity cas-
es. Moreover, the results reflect local trends over a limited
period of four (Basel) and five years (Bern).
Our study has limitations. The study was retrospective, and
the study duration was too short to reliably determine time
trends, for which longer studies would be more appropri-
ate. Due to the limited dataset, some significant results
could be spurious findings, and further studies with an in-
dependent set of data would be necessary to replicate and
validate these findings, rendering them more robust. We
used self-reports as references, which carries the risk of re-
porting biases and may vary in accuracy. Moreover, data
from the two ED may reflect a regional trend and may not
be representative of the whole country. Some symptoms
could have been due to withdrawal and not due to acute
substance toxicity (e.g. seizures in case of benzodiazepine
withdrawal). Severe intoxications may have been overrep-
resented because of the co-use of alcohol or other psy-
choactive substances in many cases. Some patients were
transferred directly from the ED to the psychiatric ward
without a full check-up. In these cases the data retrieved
were limited. Furthermore, the source of abused prescrip-
tion/OTC drugs (e.g. black market, prescription, internet)
is often not reported and thus important information for
combatting the abuse remains unaccounted for.
We regard the search algorithm, which provides us with
a detailed and sensitive search result, and the manual re-
view of all cases as a strength of this study. Our study is
not based solely on coded diagnoses or laboratory results,
which carry the risk of including patients with e.g. regu-
lar or iatrogenic benzodiazepine intake. Furthermore, our
systematic data abstraction and analysis makes comparison
with similar data easier.
Conclusion
This retrospective study at two urban EDs in Switzerland
showed that most presentations due to acute recreational
prescription/OTC drug toxicity were associated with ben-
zodiazepines, methadone and other opioids. In contrast to
other countries, benzodiazepines seem to be more widely
recreationally used than opioids and/or lead to more ED at-
tendances. This potentially indicates a national trend or the
greater local availability of benzodiazepines. Furthermore,
a significant increase in presentations was seen not only
within the youngest, but also in the oldest age group and in
females in one of the study cohorts. Health care providers
should be alert to current demographic trends of prescrip-
tion/OTC abuse. This information can be used to adapt
the prevention and treatment strategies in their communi-
ties without compromising drug access to patients who use
them correctly.
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Appendix 1 Supplementary figure
Figure S1: Trends in severity of toxicity in (a) Bern, (b) Basel. Red, green and light blue = lowess (locally weighted scatterplot smoothing)
curve fit.
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